Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations.
Narang A, Gebrael G, Jo Y, Thomas VM, Li H, Fortuna GG, Sayegh N, Tandar C, Tripathi N, Chigarira B, Srivastava A, Hage Chehade C, Nordblad B, Maughan BL, Agarwal N, Swami U. Narang A, et al. Among authors: nordblad b. Kidney Cancer. 2024 Sep 5;8(1):135-142. doi: 10.3233/KCA-240016. eCollection 2024. Kidney Cancer. 2024. PMID: 39263256 Free PMC article.
Talazoparib for the treatment of prostate cancer.
Narang A, Hage Chehade C, Ozay ZI, Nordblad B, Swami U, Agarwal N. Narang A, et al. Among authors: nordblad b. Expert Opin Pharmacother. 2024 Sep;25(13):1717-1727. doi: 10.1080/14656566.2024.2397002. Epub 2024 Aug 29. Expert Opin Pharmacother. 2024. PMID: 39210559 Review.
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, Agarwal N, Swami U. Gebrael G, et al. Among authors: nordblad b. Cancer. 2024 Aug 1;130(15):2621-2628. doi: 10.1002/cncr.35302. Epub 2024 Apr 2. Cancer. 2024. PMID: 38564301
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: nordblad b. Prostate. 2024 Jun;84(9):888-892. doi: 10.1002/pros.24696. Epub 2024 Apr 1. Prostate. 2024. PMID: 38561317
Reply by Authors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: nordblad b. Urol Pract. 2023 Oct 30:101097UPJ000000000000047102. doi: 10.1097/UPJ.0000000000000471.02. Online ahead of print. Urol Pract. 2023. PMID: 37903752 No abstract available.
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Mathew Thomas V, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: nordblad b. Urol Pract. 2024 Jan;11(1):32-35. doi: 10.1097/UPJ.0000000000000471. Epub 2023 Oct 30. Urol Pract. 2024. PMID: 37903742
11 results